Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study ⁎
Journal article published in 2018 by
Francesca Palandri,
Giuseppe A. Palumbo 
,
Alessandra Iurlo,
Nicola Polverelli ,
Giulia Benevolo,
Massimo Breccia,
Elisabetta Abruzzese ,
Mario Tiribelli,
Massimiliano Bonifacio ,
Alessia Tieghi,
Alessandro Isidori,
Bruno Martino,
Nicola Sgherza,
Mariella D'Adda,
Micaela Bergamaschi
and other authors.
,
Alessandra Iurlo,
Nicola Polverelli ,
Giulia Benevolo,
Massimo Breccia,
Elisabetta Abruzzese ,
Mario Tiribelli,
Massimiliano Bonifacio ,
Alessia Tieghi,
Alessandro Isidori,
Bruno Martino,
Nicola Sgherza,
Mariella D'Adda,
Micaela Bergamaschi
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 